Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company's Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation

Access the segment here SOUTH SAN FRANCISCO, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it participated in a Virtual Investor CEO Connect Segment. As part of the segment, Timothy Lu, MD, PhD, CEO of Senti, discussed its recent news release announcing that the U.S. Food and Drug Administration (FDA) gra ...